Advertisement
Review Article| Volume 39, ISSUE 1, P171-183, March 2019

Download started.

Ok

Signaling Molecules in Posttransplantation Cancer

Published:December 17, 2018DOI:https://doi.org/10.1016/j.cll.2018.10.006

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Au E.
        • Wong G.
        • Chapman J.R.
        Cancer in kidney transplant recipients.
        Nat Rev Nephrol. 2018; 14: 508-520
        • Sprangers B.
        • Nair V.
        • Launay-Vacher V.
        • et al.
        Risk factors associated with post-kidney transplant malignancies: an article from the Cancer-Kidney International Network.
        Clin Kidney J. 2018; 11: 315-329
        • van de Wetering J.
        • Roodnat J.I.
        • Hemke A.C.
        • et al.
        Patient survival after the diagnosis of cancer in renal transplant recipients: a nested case-control study.
        Transplantation. 2010; 90: 1542-1546
        • Hall E.C.
        • Pfeiffer R.M.
        • Segev D.L.
        • et al.
        Cumulative incidence of cancer after solid organ transplantation.
        Cancer. 2013; 119: 2300-2308
        • Engels E.A.
        • Pfeiffer R.M.
        • Fraumeni Jr., J.F.
        • et al.
        Spectrum of cancer risk among US solid organ transplant recipients.
        JAMA. 2011; 306: 1891-1901
        • Akhtar M.Z.
        • Sutherland A.I.
        • Huang H.
        • et al.
        The role of hypoxia-inducible factors in organ donation and transplantation: the current perspective and future opportunities.
        Am J Transplant. 2014; 14: 1481-1487
        • Balan M.
        • Chakraborty S.
        • Flynn E.
        • et al.
        Honokiol inhibits c-Met-HO-1 tumor-promoting pathway and its cross-talk with calcineurin inhibitor-mediated renal cancer growth.
        Sci Rep. 2017; 7: 5900
        • Akhtar M.Z.
        • Henderson T.
        • Sutherland A.
        • et al.
        Novel approaches to preventing ischemia-reperfusion injury during liver transplantation.
        Transplant Proc. 2013; 45: 2083-2092
        • Basu A.
        • Contreras A.G.
        • Datta D.
        • et al.
        Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer.
        Cancer Res. 2008; 68: 5689-5698
        • Jung J.W.
        • Overgaard N.H.
        • Burke M.T.
        • et al.
        Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients?.
        Int J Cancer. 2016; 138: 281-292
        • Perez C.P.
        • Patel N.
        • Mardis C.R.
        • et al.
        Belatacept in solid organ transplant: review of current literature across transplant types.
        Transplantation. 2018; 102: 1440-1452
        • Gaumann A.
        • Schlitt H.J.
        • Geissler E.K.
        Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.
        Transpl Int. 2008; 21: 207-217
        • Datta D.
        • Contreras A.G.
        • Basu A.
        • et al.
        Calcineurin inhibitors activate the proto-oncogene Ras and promote protumorigenic signals in renal cancer cells.
        Cancer Res. 2009; 69: 8902-8909
        • Datta D.
        • Contreras A.G.
        • Grimm M.
        • et al.
        Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression.
        J Am Soc Nephrol. 2008; 19: 2437-2446
        • Basu A.
        • Banerjee P.
        • Contreras A.G.
        • et al.
        Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40.
        PLoS One. 2011; 6: e23919
        • Hojo M.
        • Morimoto T.
        • Maluccio M.
        • et al.
        Cyclosporine induces cancer progression by a cell-autonomous mechanism.
        Nature. 1999; 397: 530-534
        • Martinez O.M.
        • de Gruijl F.R.
        Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients.
        Am J Transplant. 2008; 8: 2205-2211
        • Thurau M.
        • Marquardt G.
        • Gonin-Laurent N.
        • et al.
        Viral inhibitor of apoptosis vFLIP/K13 protects endothelial cells against superoxide-induced cell death.
        J Virol. 2009; 83: 598-611
        • Abboud E.R.
        • Shelby B.D.
        • Angelova M.
        • et al.
        Kaposi sarcoma-associated herpesvirus g protein-coupled receptor enhances endothelial cell survival in part by upregulation of bcl-2.
        Ochsner J. 2013; 13: 66-75
        • Jham B.C.
        • Montaner S.
        The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor: lessons on dysregulated angiogenesis from a viral oncogene.
        J Cell Biochem. 2010; 110: 1-9
        • Tomaic V.
        Functional roles of E6 and E7 oncoproteins in HPV-induced malignancies at diverse anatomical sites.
        Cancers (Basel). 2016; 8 ([pii:E95])
        • Zemel R.
        • Issachar A.
        • Tur-Kaspa R.
        The role of oncogenic viruses in the pathogenesis of hepatocellular carcinoma.
        Clin Liver Dis. 2011; 15 (vii–x): 261-279
        • Rovira J.
        • Renner P.
        • Sabet-Baktach M.
        • et al.
        Cyclosporine A inhibits the T-bet-dependent antitumor response of CD8(+) T cells.
        Am J Transplant. 2016; 16: 1139-1147
        • Datta A.
        • David R.
        • Glennie S.
        • et al.
        Differential effects of immunosuppressive drugs on T-cell motility.
        Am J Transplant. 2006; 6: 2871-2883